Protein Arginine Deiminase 2 (PAD2) is a guanidino-modifying enzyme that catalyzes the conversion of specific arginine residues to citrulline in a calcium-dependent manner. This enzyme has been implicated in several diseases, including rheumatoid arthritis (RA), retinal degeneration, and certain cancers. PAD2 has been shown to modify vimentin, fibrinogen and β/γ-actin. Extracellular levels of PAD2 are increased in the lungs of smokers, providing a link between smoking as a risk factor for RA and anti-citrullinated protein antibodies among RA patients. Cayman’s PAD2 Inhibitor Screening Assay (Ammonia) provides a convenient method for screening human PAD2 inhibitors.
Available on backorder
Formulation:
Formal name:
Synonyms: PAD-H19|PADI2|Peptidylarginine Deiminase 2|Protein Arginine Deiminase 2
Host:
Imunogen:
Applications:
Clone:
Purity:
Origin:
Application|Fluorescence||Application|High-Throughput Screening||Product Type|Assay Kits|Fluorometric Assays||Product Type|Assay Kits|Inhibitor Screening Assays||Research Area|Epigenetics, Transcription, & Translation|Writers|Citrullination||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis
For quantitative detection of human NCAN in cell culture supernates, serum and plasma (heparin, EDTA, citrate).
Available on backorder
For quantitative detection of rat BMPER in cell culture supernates, serum and plasma (heparin, EDTA, citrate).
Available on backorder
For quantitative detection of human LAIR1 in cell culture supernates, serum and plasma (heparin, EDTA, citrate).
Available on backorder
